Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HSDD

- PMLiVE

Valeant offers $45.7bn for Botox firm Allergan

Trend for major pharma deals continues

Valeant appoints company group chairman

Ari Kellen joins from McKinsey & Company

- PMLiVE

Valeant to slash workforce after Bausch + Lomb takeover

Expects job cuts of 10 to 15 per cent

- PMLiVE

Onyx rejects $10bn takeover bid from Amgen

Says offer is too low, but doesn't rule out a deal

- PMLiVE

GSK/ Valeant’s Trobalt set for EU restrictions

Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug

- PMLiVE

Valeant buys Bausch + Lomb for $8.7bn

Biggest deal yet for acquisition-hungry Canadian pharma company

- PMLiVE

Rumoured Valeant merger with Actavis stalls

Wall Street Journal claims talks have fallen through on $13bn merger

- PMLiVE

Merz pulls out of race for Obagi Medical

Leaves Valeant open to complete takeover

- PMLiVE

Battle lines drawn as Valeant ups Obagi bid

Hits back against Merz offer

- PMLiVE

Merz offers $385m to trump Valeant’s bid for Obagi

Could spark bidding war for dermatology specialist

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

Valeant appoints Howard Schiller to the board

He joins at a time of expansion for the Canadian pharma company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links